Ranolazine Tablets

Mechanism

Ranolazine is an anti-anginal medication primarily used for the treatment of chronic stable angina. It exerts its therapeutic effect by selectively inhibiting the late inward sodium current (late INa) in cardiac myocytes.

Pharmacokinetics

• Absorption: Oral bioavailability ~35–50%; peak plasma levels in 2–5 hrs.
• Distribution: ~62% protein bound.
• Metabolism: Extensively metabolized hepatically via CYP3A and CYP2D6.
• Excretion: Renal and fecal excretion.
• Half-life: ~7 hrs.

Side Effects

• Dizziness
• Constipation
• Nausea
• Headache
• Rare: QT prolongation

Contraindication

• Severe hepatic impairment
• Concomitant use with strong CYP3A inhibitors (e.g., ketoconazole)
• Hypersensitivity to Ranolazine

Interaction

• CYP3A inhibitors ↑ ranolazine levels
• CYP3A inducers ↓ ranolazine efficacy
• Other QT-prolonging drugs ↑ arrhythmia risk

Warning and Precautions

• Monitor ECG for QT prolongation
• Use cautiously in renal impairment
• Adjust dose in elderly patients

Dosage

As directed by the Physician.